Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30;12(29):18973-18984.
doi: 10.1039/d2ra03163a. eCollection 2022 Jun 22.

Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors

Affiliations

Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors

Sjors van Klaveren et al. RSC Adv. .

Abstract

Galectins are galactoside-binding proteins that play a role in various pathophysiological conditions, making them attractive targets in drug discovery. We have designed and synthesised a focused library of aromatic 3-triazolyl-1-thiogalactosides targeting their core site for binding of galactose and a subsite on its non-reducing side. Evaluation of their binding affinities for galectin-1, -3, and -8N identified acetamide-based compound 36 as a suitable compound for further affinity enhancement by adding groups at the reducing side of the galactose. Synthesis of its dichlorothiophenyl analogue 59 and the thiodigalactoside analogue 62 yielded promising pan-galectin inhibitors.

PubMed Disclaimer

Conflict of interest statement

H. L. and U. J. N. are shareholders in Galecto Biotech AB, a company developing galectin inhibitors. The other authors have no conflicts to declare.

Figures

Fig. 1
Fig. 1. (A): Alignment of galectin CRD crystal structures indicating binding subsites A–E. Residues are shown as green (galectin-1, PDB code: 5MWX), cyan (galectin-3, PDB code: 6QLN), and salmon (galectin-8N, PDB code: 7AEN) coloured sticks. (B): Crystal structure of galectin-1 in complex with ligand JB60 (PDB code 5MWK). (C): Crystal structure of galectin-3 in complex with a fluoroaryltriazole disaccharide (PDB code 6QLN). (D): Crystal structure of galectin-8N in complex with a quinolinyl galactopyranoside (PDB code 7AEN). In all structures, the ligand is shown in sticks with white carbons, with the galactose moiety shown in purple to emphasise the predominant binding of the sugar moiety in subsite C. This galactose moiety of the ligands binds between a Trp68 and Arg48 in galectin-1; Trp181 and Arg162 in galectin-3; and Trp86 and Arg69 in galectin-8N.
Fig. 2
Fig. 2. Selected known galectin inhibitors with triazolyl groups or related functionalities.
Scheme 1
Scheme 1. Synthesis of optimised acetamide ligands.
Fig. 3
Fig. 3. Schematic representation of interaction analysis from MD simulations. (A) Galectin-1, (B) galectin-3 and (C) galectin-8N. Hydrogen and halogen bonds are shown as black and pink dashed lines, respectively. Cation–π interaction is presented as red line, while hydrophobic interactions are presented as grey curved line. For clarity of presentation, interactions with galactose moieties are not shown.
Fig. 4
Fig. 4. Molecular dynamics snapshots of compounds 62 and 59 in galectin-1, -3, and -8N. (A) and (D) The CRD of galectin-1 with compounds 62 and 59, respectively. (B) and (E) The CRD of galectin-3 with compounds 62 and 59, respectively. (C) and (F) The CRD of galectin-8N with compounds 62 and 59, respectively. Ligands are shown as white sticks with standard atom colouring. Residues are shown as sticks carbon-coloured green (galectin-1), cyan (galectin-3), and salmon (galectin-8N).

Similar articles

Cited by

References

    1. Barondes S. H. Castronovo V. Cooper D. N. Cummings R. D. Drickamer K. Feizi T. Gitt M. A. Hirabayashi J. Hughes C. Kasai K. Cell. 1994;76:597–598. doi: 10.1016/0092-8674(94)90498-7. - DOI - PubMed
    1. Nabi I. R. Shankar J. Dennis J. W. J. Cell Sci. 2015;128:2213–2219. doi: 10.1242/jcs.151159. - DOI - PubMed
    1. Johannes L. Jacob R. Leffler H. J. Cell Sci. 2018;131:jcs208884. doi: 10.1242/jcs.208884. - DOI - PubMed
    1. Girotti M. R. Salatino M. Dalotto-Moreno T. Rabinovich G. A. J. Exp. Med. 2019;217:e20182041. doi: 10.1084/jem.20182041. - DOI - PMC - PubMed
    1. Cummings R. D., Liu F.-T. and Vasta G. R., in Essentials of Glycobiology, ed. A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, A. G. Darvill, T. Kinoshita, N. H. Packer, J. H. Prestegard, R. L. Schnaar and P. H. Seeberger, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY), 3rd edn, 2015 - PubMed